112 related articles for article (PubMed ID: 30783360)
1. Hypolipidemic effect of
Patel B; Kamble SB; Vyas HA; Vyas MK; Chinthala R
Ayu; 2018; 39(2):72-75. PubMed ID: 30783360
[TBL] [Abstract][Full Text] [Related]
2. The utility of non-HDL in managing dyslipidemia of stage 5 chronic kidney disease.
Pennell P; Leclercq B; Delahunty MI; Walters BA
Clin Nephrol; 2006 Nov; 66(5):336-47. PubMed ID: 17140163
[TBL] [Abstract][Full Text] [Related]
3. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
Wong ND; Chuang J; Zhao Y; Rosenblit PD
J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
[TBL] [Abstract][Full Text] [Related]
4. Dyslipidemia and its association with meibomian gland dysfunction.
Braich PS; Howard MK; Singh JS
Int Ophthalmol; 2016 Aug; 36(4):469-76. PubMed ID: 26515235
[TBL] [Abstract][Full Text] [Related]
5. Practical management of dyslipidemia with elevated lipoprotein(a).
Riche DM; East HE; Priest HM
J Am Pharm Assoc (2003); 2008; 48(6):803-7. PubMed ID: 19019811
[TBL] [Abstract][Full Text] [Related]
6. A comparative clinical study of Asanadi Ghanavati and Gomutra Haritaki in Kapha Medo Margavarana (dyslipidemia).
Joshi SG; Chandola HM; Dave AR
Ayu; 2014 Apr; 35(2):152-9. PubMed ID: 25558160
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of dyslipidemia and associated risk factors in Turkish adults.
Bayram F; Kocer D; Gundogan K; Kaya A; Demir O; Coskun R; Sabuncu T; Karaman A; Cesur M; Rizzo M; Toth PP; Gedik V
J Clin Lipidol; 2014; 8(2):206-16. PubMed ID: 24636181
[TBL] [Abstract][Full Text] [Related]
8. Significant Impact of the Ketogenic Diet on Low-Density Lipoprotein Cholesterol Levels.
Salas Noain J; Minupuri A; Kulkarni A; Zheng S
Cureus; 2020 Jul; 12(7):e9418. PubMed ID: 32864246
[TBL] [Abstract][Full Text] [Related]
9. Association of dyslipidemia in moderate to severe meibomian gland dysfunction.
Dao AH; Spindle JD; Harp BA; Jacob A; Chuang AZ; Yee RW
Am J Ophthalmol; 2010 Sep; 150(3):371-375.e1. PubMed ID: 20619393
[TBL] [Abstract][Full Text] [Related]
10. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
Ray KK; Del Prato S; Müller-Wieland D; Cariou B; Colhoun HM; Tinahones FJ; Domenger C; Letierce A; Mandel J; Samuel R; Bujas-Bobanovic M; Leiter LA
Cardiovasc Diabetol; 2019 Nov; 18(1):149. PubMed ID: 31706300
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of coadministration of fenofibrate and ezetimibe compared with each as monotherapy in patients with type IIb dyslipidemia and features of the metabolic syndrome: a prospective, randomized, double-blind, three-parallel arm, multicenter, comparative study.
Ansquer JC; Bekaert I; Guy M; Hanefeld M; Simon A;
Am J Cardiovasc Drugs; 2009; 9(2):91-101. PubMed ID: 19331437
[TBL] [Abstract][Full Text] [Related]
12. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
Rosenblit PD
Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
[TBL] [Abstract][Full Text] [Related]
13. Lifetime risk for developing dyslipidemia: the Framingham Offspring Study.
Cobain MR; Pencina MJ; D'Agostino RB; Vasan RS
Am J Med; 2007 Jul; 120(7):623-30. PubMed ID: 17602937
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of lipid abnormalities in the United States: the National Health and Nutrition Examination Survey 2003-2006.
Tóth PP; Potter D; Ming EE
J Clin Lipidol; 2012; 6(4):325-30. PubMed ID: 22836069
[TBL] [Abstract][Full Text] [Related]
15. Serum lipid profiles including non-high density lipoprotein cholesterol levels in Turkish school-children.
Uçar B; Kiliç Z; Dinleyici EC; Colak O; Güneş E
Anadolu Kardiyol Derg; 2007 Dec; 7(4):415-20. PubMed ID: 18065339
[TBL] [Abstract][Full Text] [Related]
16. Serum lipid and lipoprotein profile abnormality in predicting the risk of coronary artery disease in non-diabetic patients attending NMCTH, Birgunj.
Adak M; Shivapuri JN
Nepal Med Coll J; 2010 Sep; 12(3):158-64. PubMed ID: 21446364
[TBL] [Abstract][Full Text] [Related]
17. Impact of Novel Low-Density Lipoprotein-Cholesterol Assessment on the Utility of Secondary Non-High-Density Lipoprotein-C and Apolipoprotein B Targets in Selected Worldwide Dyslipidemia Guidelines.
Sathiyakumar V; Park J; Quispe R; Elshazly MB; Michos ED; Banach M; Toth PP; Whelton SP; Blumenthal RS; Jones SR; Martin SS
Circulation; 2018 Jul; 138(3):244-254. PubMed ID: 29506984
[TBL] [Abstract][Full Text] [Related]
18. Metabolic Dyslipidemia and Risk of Coronary Heart Disease in 28,318 Adults With Diabetes Mellitus and Low-Density Lipoprotein Cholesterol <100 mg/dl.
Rana JS; Liu JY; Moffet HH; Solomon MD; Go AS; Jaffe MG; Karter AJ
Am J Cardiol; 2015 Dec; 116(11):1700-4. PubMed ID: 26428026
[TBL] [Abstract][Full Text] [Related]
19. Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels.
Querton L; Buysschaert M; Hermans MP
J Clin Lipidol; 2012; 6(5):434-42. PubMed ID: 23009779
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
